AbCellera reported positive Phase 2 results for its NK3R-targeting program in a trial for vasomotor symptoms, or hot flashes. The company said the dataset beat Wall Street expectations, driving a sharp share gain shortly after the announcement.
Get the Daily Brief
AbCellera reported positive Phase 2 results for its NK3R-targeting program in a trial for vasomotor symptoms, or hot flashes. The company said the dataset beat Wall Street expectations, driving a sharp share gain shortly after the announcement.